There were no significant differences (p > 0.05) in blood glucose, total cholesterol or triglyceride levels at 28 days after stroke among T2DM, T2DM-stroke and CD133 + Exo treated T2DM-stroke mice (Figure 1F). This evidence concerns the gene PROM1 and stroke disorder.